Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic.

Rifaximin (4-deoxy-4'-methylpyrido[1',2'-1,2]imidazo [5,4-c]rifamycin SV) is a product of synthesis experiments designed to modify the parent compound, rifamycin, in order to achieve low gastrointestinal (GI) absorption while retaining good antibacterial activity. Both experimental and clinical pharmacology clearly show that this compound is a non-systemic antibiotic with a broad spectrum of antibacterial action covering Gram-positive and Gram-negative organisms, both aerobes and anaerobes. Being virtually non-absorbed, its bioavailability within the GI tract is rather high with intraluminal and fecal drug concentrations that largely exceed the minimum inhibitory concentration values observed in vitro against a wide range of pathogenic organisms. The GI tract represents therefore the primary therapeutic target and GI infections the main indication. This antibiotic has therefore little value outside the enteric area and this will minimize both antimicrobial resistance and systemic adverse events. Indeed, the drug proved to be safe in all patient populations, including young children. The appreciation of the pathogenic role of gut bacteria in several organic and functional GI diseases has increasingly broadened its clinical use, which is now extended to hepatic encephalopathy, small intestine bacterial overgrowth, inflammatory bowel disease and colonic diverticular disease.

[1]  K. Hirose,et al.  Aminoglycoside ototoxicity , 2007, Current opinion in otolaryngology & head and neck surgery.

[2]  Naohiro Matsugaki,et al.  Allosteric Modulation of the RNA Polymerase Catalytic Reaction Is an Essential Component of Transcription Control by Rifamycins , 2005, Cell.

[3]  G. Piccoli,et al.  A dance teacher with kidney-pancreas transplant and diarrhoea: what is the cause? , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[4]  A Randomized, Double-Blind, Placebo-Controlled Trial of Rifaximin to Prevent Travelers’ Diarrhea , 2005 .

[5]  H. Dupont,et al.  Rifaximin in the Treatment of Infectious Diarrhea , 2005, Chemotherapy.

[6]  C. Papi,et al.  Management of Diverticular Disease: Is There Room for Rifaximin? , 2005, Chemotherapy.

[7]  H. Dupont,et al.  Rifaximin: In vitro and in vivo Antibacterial Activity – A Review , 2005, Chemotherapy.

[8]  G. Corazza,et al.  Treatment of Small Intestine Bacterial Overgrowth and Related Symptoms by Rifaximin , 2005, Chemotherapy.

[9]  C. Scarpignato,et al.  Rifaximin, a Poorly Absorbed Antibiotic: Pharmacology and Clinical Potential , 2005, Chemotherapy.

[10]  M. Baraldi,et al.  Management of Hepatic Encephalopathy: Role of Rifaximin , 2005, Chemotherapy.

[11]  E. Husebye The Pathogenesis of Gastrointestinal Bacterial Overgrowth , 2005, Chemotherapy.

[12]  Laura N. Gerard,et al.  Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections , 2005, Expert review of anti-infective therapy.

[13]  H. Dupont,et al.  Rifaximin--a novel antimicrobial for enteric infections. , 2005, The Journal of infection.

[14]  S. Poutanen,et al.  Clostridium difficile-associated diarrhea in adults , 2004, Canadian Medical Association Journal.

[15]  R. Frye Probing the world of cytochrome P450 enzymes. , 2004, Molecular interventions.

[16]  H. Boxenbaum,et al.  The effect of rifaximin on the pharmacokinetics of a single dose of ethinyl estradiol and norgestimate in healthy female volunteers , 2004 .

[17]  H. Boxenbaum,et al.  The effect of rifaximin on the pharmacokinetics (PK) of single doses of intravenous (IV) and oral (PO) midazolam in healthy volunteers , 2004 .

[18]  H. Dupont Community-acquired diarrheal disease in western countries: Applications of nonabsorbable oral antibiotic therapy , 2003 .

[19]  M. Scrascia,et al.  Susceptibility to rifaximin of Vibrio cholerae strains from different geographical areas. , 2003, The Journal of antimicrobial chemotherapy.

[20]  M. Montecalvo Ramoplanin: a novel antimicrobial agent with the potential to prevent vancomycin-resistant enterococcal infection in high-risk patients. , 2003, The Journal of antimicrobial chemotherapy.

[21]  B. Lowe,et al.  Therapy of travelers’ diarrhea with rifaximin on various continents , 2003, American Journal of Gastroenterology.

[22]  S. Ito,et al.  Drug excretion into breast milk--overview. , 2003, Advanced drug delivery reviews.

[23]  A. Tursi,et al.  Assessment of orocaecal transit time in different localization of Crohn's disease and its possible influence on clinical response to therapy , 2003, European journal of gastroenterology & hepatology.

[24]  M. Montalto,et al.  Eradication of small intestinal bacterial overgrowth and oro-cecal transit in diabetics. , 2002, Hepato-gastroenterology.

[25]  E. Baker,et al.  Aminoglycoside antibiotic resistance by enzymatic deactivation. , 2002, Current drug targets. Infectious disorders.

[26]  S. Gillespie,et al.  Evolution of Drug Resistance in Mycobacterium tuberculosis: Clinical and Molecular Perspective , 2002, Antimicrobial Agents and Chemotherapy.

[27]  J. Olsen,et al.  A population-based case-control study of the safety of oral anti-tuberculosis drug treatment during pregnancy. , 2001, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[28]  L B Reller,et al.  Practice guidelines for the management of infectious diarrhea. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  M. Stockwell Gentamicin ear drops and ototoxicity: update. , 2001, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[30]  E. Palazzini,et al.  In Vitro Activity and Fecal Concentration of Rifaximin after Oral Administration , 2000, Antimicrobial Agents and Chemotherapy.

[31]  A. Marchese,et al.  In vitro Activity of Rifaximin, Metronidazole and Vancomycin against Clostridium difficile and the Rate of Selection of Spontaneously Resistant Mutants against Representative Anaerobic and Aerobic Bacteria, Including Ammonia-Producing Species , 2000, Chemotherapy.

[32]  R. Yuan,et al.  Pharmacokinetic and Pharmacodynamic Consequences of Metabolism‐Based Drug Interactions with Alprazolam, Midazolam, and Triazolam , 1999, Journal of clinical pharmacology.

[33]  C. Colomba,et al.  Intestinal protozoa in HIV-infected patients: effect of rifaximin in Cryptosporidium parvum and Blastocystis hominis infections. , 1999, Journal of chemotherapy.

[34]  P. Gionchetti,et al.  Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial. , 1999, Digestive diseases and sciences.

[35]  P. Brigidi,et al.  Antibiotic combination therapy in patients with chronic, treatment‐resistant pouchitis , 1999, Alimentary pharmacology & therapeutics.

[36]  C. Surawicz,et al.  Pseudomembranous Colitis: Causes and Cures , 1999, Digestion.

[37]  S. Traniello,et al.  3-(Carboxyalkylthio) Rifamycin S and SV Derivatives Inhibit Human Neutrophil Functions , 1998, Inflammation.

[38]  P. Gionchetti,et al.  Rifaximin systemic absorption in patients with ulcerative colitis , 1998, European Journal of Clinical Pharmacology.

[39]  H. Taber,et al.  Drug resistance in tuberculosis. , 1997, Infectious disease clinics of North America.

[40]  J. Caruso Twenty Years of Experience with Intra-Articular Rifamycin for Chronic Arthritides , 1997, The Journal of international medical research.

[41]  S. Traniello,et al.  Rifamycins Inhibit Human Neutrophil Functions: New Derivatives with Potential Antiinflammatory Activity , 1997, Inflammation.

[42]  L. Barbara,et al.  The susceptibility of Helicobacter pylori to the rifamycin, rifaximin. , 1995, The Journal of antimicrobial chemotherapy.

[43]  P. Speelman,et al.  Role of antibiotics in the treatment and prevention of acute and recurrent cholangitis. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[44]  B. Spratt Resistance to antibiotics mediated by target alterations. , 1994, Science.

[45]  F. Mégraud,et al.  In vitro activity of rifaximin againstHelicobacter pylori , 1994, European Journal of Clinical Microbiology and Infectious Diseases.

[46]  R. Polk,et al.  Pharmacokinetic Drug Interactions with Antimicrobial Agents , 1993, Clinical pharmacokinetics.

[47]  E. Prasad,et al.  In vitro activity of rifaximin, a topical rifamycin derivative, against Chlamydia trachomatis. , 1993, Diagnostic microbiology and infectious disease.

[48]  G. Eliopoulos,et al.  Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative. , 1993, Diagnostic microbiology and infectious disease.

[49]  S. Stanley,et al.  The role of newer antibiotics in gastroenterology. , 1992, Gastroenterology Clinics of North America.

[50]  S. Santandrea,et al.  Clinical Improvement in Ankylosing Spondylitis with Rifamycin SV Infiltrations of Peripheral Joints , 1992, The Journal of international medical research.

[51]  C. Ellis,et al.  Review article: antibiotics and the gut , 1989, Alimentary pharmacology & therapeutics.

[52]  J. Dipiro,et al.  Vancomycin: An Update , 1986, Pharmacotherapy.

[53]  E. Marchi,et al.  4-Deoxypyrido[1',2':1,2]imidazo[5,4-c]rifamycin SV derivatives. A new series of semisynthetic rifamycins with high antibacterial activity and low gastroenteric absorption. , 1985, Journal of medicinal chemistry.

[54]  G. Zanolo,et al.  Rifaximin (L/105), a new topical intestinal antibiotic: pharmacokinetic study after single oral administration of 3H-rifaximin to rats. , 1984, Chemioterapia : international journal of the Mediterranean Society of Chemotherapy.

[55]  A. Lamanna,et al.  In vitro activity of rifaximin and rifampicin against some anaerobic bacteria. , 1984, Chemioterapia : international journal of the Mediterranean Society of Chemotherapy.

[56]  K. Kavanagh,et al.  Ototoxicity of Oral Neomycin and Vancomycin , 1983, The Laryngoscope.

[57]  K. Howell Traveller's Diarrhoea , 1982, The Lancet.

[58]  R. Bryant,et al.  Neomycin absorption in man. Studies of oral and enema administration and effect of intestinal ulceration. , 1972, Annals of internal medicine.

[59]  T. Chalmers,et al.  Deafness complicating antibiotic therapy of hepatic encephalopathy. , 1970, Annals of internal medicine.

[60]  G. Lancini,et al.  Rifamycins LXI: In vivo inhibition of RNA synthesis by rifamycins , 1968, Experientia.

[61]  K. Nitta,et al.  Inhibition of DNA-dependent RNA synthesis by rifamycins. , 1968, The Journal of antibiotics.

[62]  H. J. Simon Streptomycin, kanamycin, neomycin and paromomycin. , 1968, Pediatric clinics of North America.

[63]  T. Chalmers,et al.  Absorption of orally administered neomycin and kanamycin with special reference to patients with severe hepatic and renal disease. , 1960, The New England journal of medicine.

[64]  P. Fenstemacher Practice Guidelines for the Management of Infectious Diarrhea , 2007 .

[65]  Roger Williams,et al.  Rifaximin, a nonabsorbed oral antibiotic, in the treatment of hepatic encephalopathy: antimicrobial activity, efficacy, and safety. , 2005, Reviews in gastroenterological disorders.

[66]  D. Baker Rifaximin: a nonabsorbed oral antibiotic. , 2005, Reviews in gastroenterological disorders.

[67]  X. Calvet,et al.  [Evaluation of Helicobacter pylori susceptibility to rifaximin]. , 2004, Gastroenterologia y hepatologia.

[68]  R. Kruger,et al.  Chemistry and biology of the ramoplanin family of peptide antibiotics. , 2002, Biopolymers.

[69]  M. Hugin,et al.  Drug interactions between oral contraceptives and antibiotics. , 2002, Obstetrics and gynecology.

[70]  Ramoplanin. A 16686, A 16686A, MDL 62198. , 2002, Drugs in R&D.

[71]  J. Olsen,et al.  A teratological study of aminoglycoside antibiotic treatment during pregnancy. , 2000, Scandinavian journal of infectious diseases.

[72]  G. Wright,et al.  Aminoglycoside antibiotics. Structures, functions, and resistance. , 1998, Advances in experimental medicine and biology.

[73]  H. Debruyne,et al.  A prospective study in healthy volunteers of the topical absorption of a 5% rifaximin cream. , 1994, Drugs under experimental and clinical research.

[74]  D. Dubourg,et al.  Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. , 1994, International journal of clinical pharmacology research.

[75]  R. N. Brogden,et al.  Teicoplanin. A reappraisal of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. , 1994, Drugs.

[76]  M. Prenna,et al.  In vitro antibacterial activity of rifaximin against Clostridium difficile, Campylobacter jejunii and Yersinia spp. , 1987, Drugs under experimental and clinical research.

[77]  E. Marchi,et al.  Transcutaneous absorption of a topical rifamycin preparation: rifaximin (L/105). , 1987, Drugs under experimental and clinical research.

[78]  S. Norrby Principles for targeted antibiotic use in urinary tract and enteric infections: a review with special emphasis on norfloxacin. , 1986, Scandinavian Journal of Infectious Diseases. Supplementum.

[79]  C. Eftimiadi,et al.  Rapid disappearance from the intestinal tract of bacteria resistant to rifaximin. , 1986, Drugs under experimental and clinical research.

[80]  R. Testa,et al.  A non-absorbable rifamycin for treatment of hepatic encephalopathy. , 1985, Drugs under experimental and clinical research.

[81]  M. Sande,et al.  The use of rifampicin in staphylococcal infections--a review. , 1984, The Journal of antimicrobial chemotherapy.

[82]  A. P. Venturini Pharmacokinetics of L/105, a new rifamycin, in rats and dogs, after oral administration. , 1983, Chemotherapy.

[83]  S. Barriere,et al.  Prevention and treatment of "traveler's diarrhea". , 1983, Drug intelligence & clinical pharmacy.